Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 14/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415106 | 0.82 | MEN1 (0.47) | MEN1KMT2ATLR2CA2 | |
| Alafosalin SCHEMBL1582384 | 0.81 | ANPEP (0.45) | ANPEPALDH1A1TDP1 | |
| Alafosalin SCHEMBL6908702 | 0.81 | ANPEP (0.45) | ANPEPALDH1A1TDP1 | |
| SCHEMBL13255060 | 0.80 | MEN1 (0.59) | MEN1KMT2ATLR2CA2ANPEP | |
| SCHEMBL2415111 | 0.78 | MEN1 (0.43) | MEN1KMT2ATLR2CA2 | |
| SCHEMBL22307909 | 0.77 | MEN1 (0.55) | MEN1KMT2ATLR2CA2ANPEP | |
| SCHEMBL9122686 | 0.77 | MEN1 (0.55) | MEN1KMT2ATLR2CA2ANPEP | |
| SCHEMBL13360298 | 0.76 | MEN1 (0.54) | MEN1KMT2ATLR2CA2ANPEP | |
| SCHEMBL23610794 | 0.76 | MEN1 (0.47) | MEN1KMT2ACA2ALDH1A1TDP1 | |
| SCHEMBL7397789 | 0.76 | MEN1 (0.47) | MEN1KMT2ACA2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | IRM LLC (BM) | 2014-10-30 | — | — | US | disclosed |
| US-8808703-B2 | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-08-19 | — | — | US | disclosed |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-03-14 | — | — | US | disclosed |
| EP-2549990-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | TLR2, TLR1, TLR3 | MEN1 4523/4885KMT2A 2630/4885TLR2 1/4885 |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | TLR2, TLR4, TLR3 | MEN1 4575/4885KMT2A 3127/4885TLR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.